# Deep Brain Stimulation paper review · part II

Arseny Povolotsky

三日 のへの

伺下 (日下)(日

# Outline

# Clinical results

- Optimal parameters
- Target selection
- Adverse effects

# 2 How it works?

- Mechanisms of stimulation
- Theoretical models
- Neuroprotection issues

# 3 Summary

ELE DOG

Optimal parameters Target selection Adverse effects


# **Optimal parameters**

- Monopolar cathodic stimulation
- Pulse width:  $60-200 \ \mu s$
- Stimulus frequency: 120–180 Hz
- Stimulation amplitude: 1–5 V

▲冊 ▲ ヨ ▶ ▲ ヨ ▶ ヨ ヨ め Q @

Optimal parameters Target selection Adverse effects

## Target Selection Basal ganglia scheme



・ロト・(個)・(目)・(日)・(日)・

Optimal parameters Target selection Adverse effects

- Dramatic reduction of L-dopa induced dyskinesias
- Improvement of UPDRS<sup>1</sup> motor score: 30-50 %
- Levodopa dose did not change

<sup>1</sup>unified Parkinson's disease rating scale

< 17 ▶

글 에 세 글 어

ELE SQC

Optimal parameters Target selection Adverse effects

- Improvement of UPDRS motor score: 50–70%
- DBS markedly improves all cardinal symptoms of PD (akinesia, rigidity and tremor)
- Average levodopa dosage reduced by 50–65%
- Levodopa induced dyskinesias decrease
- Complete discontinuation of dopaminergic medication in 10–50% of patients

一日、「日、「日、」」

Optimal parameters Target selection Adverse effects

#### STN-DBS is considered superior to GPi-DBS

Better clinical results for most outcome variables

Worldwide most used target

STN is worldwide most used target for surgical therapy of PD

Optimal parameters Target selection Adverse effects

# Adverse effects

- Surgery related
- Hardware failure
- Stimulation related
- Medication changes related

Optimal parameters Target selection Adverse effects

## Adverse effects Surgery related

#### Severe morbidities

- Intra-cranial haemorrhage
- Chronic subdural hematoma
- Venous infarction

## Overall risk

1-3%

## How to minimize risk?

Careful trajectory planning is mandatory

Optimal parameters Target selection Adverse effects

#### Adverse effects Hardware failure

#### Possible failures

- Lead migration
- Lead extension fracture
- Short/open circuit
- Pulse generator malfunction

## Overall risk

5-25%

#### Expertise increases

Hardware problems become less frequent

< 🗇 🕨 🔸

'문▶ ▲ 문▶ '문|'님' ' 이 익 (?)

Optimal parameters Target selection Adverse effects

#### Adverse effects Stimulation related

#### Acute, but reversible side effects

- dysarthria
- paraesthesia
- tonic muscle contraction
- . . .

## These side effects are very useful

Acute stimulation induced dyskinesias indicates correct placement of stimulation electrode

◆□▶ ◆□▶ ◆三▶ ◆三▶ ●□= ◇Q@

Mechanisms of stimulation Theoretical models Neuroprotection issues

# Mechanisms of stimulation

#### HFS mimics effects of ablation

However, the fundamental mechanisms of high-frequency stimulation are still not fully elucidated

#### Frequency is a key factor

Experimental and clinical data shows stimulation frequency represents a key factor with respect to effect of DBS

Mechanisms of stimulation Theoretical models Neuroprotection issues

# Mechanisms of stimulation Main hypotheses

- Inactivation of voltage dependent ion-channels
  ⇒ depolarization blocking of neuronal transmission
- Efferent high-frequency pattern
  - $\Rightarrow$  jamming of information
- Inhibitory afferents to the target nucleus
  - $\Rightarrow$  synaptic inhibition
- Output Section Neurotransmitter depletion
  - $\Rightarrow$  synaptic failure

● ▶ ▲ 臣 ▶ ▲ 臣 ▶ ▲ 臣 ● の Q @

Mechanisms of stimulation Theoretical models Neuroprotection issues

# Theoretical models

#### Why do we need them?

- To help understanding the mechanism of DBS
- To predict (and thus beware of) some adverse effects

## How they are built?

## Simplifying assumptions:

- Finite element field of the electric field generated by electrode
- Homogenous isotropic extracellular environment
- Simplified multicompartment cable model of neuron

Mechanisms of stimulation Theoretical models Neuroprotection issues

## Theoretical models Prediction of activation pattern

- DBS induces a complex pattern of activation and inhibition of the local cells near the electrode
- Firing of the cell body of directly stimulated neurons is not necessarily representative for their efferent output
- Stimulation-induced functional decoupling between cell body and efferent projections

- E = 9900

Clinical results How it works? Summary Mechanisms of stin Theoretical models Neuroprotection iss

#### Theoretical models Prediction of the volume of tissue influenced by DBS

#### Why do we need them?

- DBS targets are relatively small
- Adjacent structures can induce adverse effects if co-stimulated

## Major drawbacks in modeling

- Highly anisotropic medium
- Disturbances of the distribution of the electric field

#### Results

- Minor variations in the range of 1mm in the electrode location within STN can have substantial changes of the activation profile
- Target exploration prior to electrode implantation is needed

< ロ > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □

Clinical results M How it works? The Summary N

Mechanisms of stimulation Theoretical models Neuroprotection issues

# Neuroprotection issues

## STN hyperactivity is a hallmark of PD

#### STN hyperactivity ↓↓

STN-mediated glutamatergic excitotoxicity on neurons of SNc

#### How DBS can help?

# STN-DBS might reduce glutamatergic drive $\Downarrow$

Neuroprotection effect

・ 同 ト ・ ヨ ト ・ ヨ

1= 990

# Summary

#### DBS is an important treatment option

- Marked benefits
- Minimal morbidity
- Number of aspects are not improved

## Key for successful intervention

- Careful patient selection
- Precise electrode implantation

# Principles of high-frequency stimulation

- Little is known
- Empirically determined parameters

< ロ > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < 回 > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □

# Looking to the future



1= 990


-

伺下 (日下)(日

# Thank you!

< □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □

# Appendix A Basal Ganglia



・ロト・(個)・(目)・(日)・(日)・

# Appendix B Glossary

#### Akinesia

Inability to initiate movement due to difficulty selecting and/or activating motor programs in the central nervous system. http://en.wikipedia.org/wiki/Akinesia

#### Bradykinesia

Slowness in the execution of movement, a feature of a number of diseases, most notably Parkinson's disease and other disorders of the basal ganglia.

http://en.wikipedia.org/wiki/Bradykinesia

・ 同 ト ・ ヨ ト ・ ヨ ト

= 990

#### Dopamine

A hormone and neurotransmitter occurring in a wide variety of animals. In the brain, dopamine functions as a neurotransmitter, activating the five types of dopamine receptor - D1, D2, D3, D4 and D5, and their variants.

http://en.wikipedia.org/wiki/Dopamine

#### Dyskinesia

Involuntary movements, similar to a tic or chorea. In the context of Parkinson's disease, dyskinesias are often the result of chronic levodopa (L-dopa) therapy.

http://en.wikipedia.org/wiki/Dyskinesia

< □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □ > < □

#### Excitotoxicity

Pathological process by which nerve cells are damaged and killed by glutamate and similar substances. Occurs when receptors for the excitatory neurotransmitter glutamate are overactivated. http://en.wikipedia.org/wiki/Excitotoxicity

#### Glutamate

One of the 20 proteinogenic amino acids (GAA/GAC codons), the most abundant fast excitatory neurotransmitter in the mammalian nervous system.

http://en.wikipedia.org/wiki/Glutamate

# Appendix B Glossary

#### Levodopa

L-DOPA (3,4-dihydroxy-L-phenylalanine) is an intermediate in dopamine biosynthesis. In clinical use, levodopa is administered in the management of Parkinson's disease.

http://en.wikipedia.org/wiki/Levodopa

#### Neuroprotection

Mechanisms within the nervous system which protect neurons from apoptosis or degeneration.

http://en.wikipedia.org/wiki/Neuroprotection

# Appendix C Abbreviations

- PD Parkinson's disease
- DBS Deep brain stimulation
- HFS High-Frequency Stimulation
- STN SubThalamic Nucleus
  - GPi Globus Pallidus internal
- GPe Globus Pallidus external
- SNc Substantia Nigra pars Compacta
- Vim Ventralis intermedius
- PPN PedunculoPontine Nucleus
- UPDRS Unified Parkinson's Disease Rating Scale